LXEO logo

LEXEO THERAPEUTICS INC

LXEONASDAQ
🏆 #3520 by market capEarnings Nov 9US Equity
$145.47▲ $1.47 (+1.01%)
Simulated price
🔔
Track LXEO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.0%
7d▲ 3474.2%
14d▲ 3409.5%
30d▲ 2890.1%
ytd▲ 1366.4%
1y▲ 2087.5%
🏦Market Cap
$260M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$144.71 – $146.47
52-Week Range
$3.27 – $10.99
Volume
$5.83B
Avg Volume
$4.21B
Shares Outstanding
78.5M
Next Earnings
Nov 18, 2026

Fundamentals Snapshot

Annual Revenue
$90M
Last Q Revenue
$22M
P/E Ratio
-2.9
P/S Ratio
0.0x
EPS (TTM)
$-1.02
Dividend Yield
0.00%
Dilution (1yr)
+130.9%

Why Investors Own LXEO

  • ✓High-growth profile — revenue up +49.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 62% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LXEO logo

LEXEO THERAPEUTICS INC

LXEO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$109M▲ +3.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$99M▲ +21.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
76.4M▲ +130.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$55M▲ +$30M YoY
StockOtter · stockotter.space

About LEXEO THERAPEUTICS INC

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$188.06
▲ +29.3% Upside
High Target$210.66
Low Target$156.03
Based on 36 analysts

Latest News & Updates

🚀
Reuters·2h ago

LEXEO THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift LXEO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

LEXEO THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.